Abiopharma

10x Genomics - 10x Genomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026

IQVIA - IQVIA Named to the Fortune® World’sMost Admired Companies™ List, Ranked No. 1 in Its Sector for Fifth Consecutive Year

Press Release: AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

agilon health - agilon health Sets Date to Report Fourth Quarter and Full Year 2025 Financial Results

CVRx Announces Initiation of BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population

10x Genomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Perimeter Solutions Completes Acquisition of MMT

Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026